But if,by what Pucci seems to be saying, the CRC data is even good, and they have to run another Phase 2, what are we looking at? Another approved CRC drug in 2018? Or another poorly designed Phase 3 study like the NSCLC?
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.